BCAT1 and neoplasm: Treatment with L-β-hydroxyisoleucine (LβhL), a leucine analog and competitive inhibitor of BCAT1, can reduce IL-17 production in TCR-activated CD4+ T cells, thus weakening the immune response in the tumor microenvironment (Kang Y. J. et al., 2024).